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Abstract 
During the past decades, research on ethical, legal, and social aspects (ELSA) of 
biobanks suggested and analysed various ethically and socially justifiable frameworks 
for collecting, storing, and distributing human biological material and bioinformation. 
In this article, we identify three patterns of argument that differ in terms of shared 
core assumptions and similar conceptual as well as normative orientations. These 
discursive ‘orders’, which are related to specific macropolitical contexts, have 
significantly shaped contexts for biobank policymaking. The first order was 
characterised by high expectations of genomics and biobanking. Second order 
discourse partly took over the problems located in the first order, but reintroduced 
them into a justificatory framework that identified biobanks as public goods per se. 
The third order of ELSA expertise maintained a supportive attitude towards 
biobanking. However, regulation based on deductive reasoning became progressively 
complemented by ideals of participatory mechanisms and different methodologies of 
studying public perceptions. We conclude that this emphasis on learning processes 
and deliberation helps biobank communities to develop new concepts, methods and 
insights that will prove helpful in order to adapt to essentially undetermined futures of 
transnational innovation societies. 
Introduction 
The role of ethics in policy discourses about biotechnological innovation has already 
received a reasonable amount of attention.2 Building on this, in this article we 
critically discuss the emergence of three ‘orders’ of research on ethical, legal, and 
social aspects (ELSA) of genetics and biotechnology, as it has developed with regard 
to biobanks in the past 15 years. 
 
We assume that the language of this ELSA discourse, like language in general3, does 
not simply mirror the world but shapes our view of it in a profound way. The space of 
biobank policymaking is therefore ordered by analysts’ ways of representing a policy 
or policy problem. These representations are necessarily selective and make 
assumptions about “causality and responsibility, about legitimacy and authority, and 
about interests, needs, values, preferences, and obligations”.4 Our analysis of 
discursive practices or orders focuses on how particular narratives privilege some 
issues or things over others and on the ways in which the language of ethical analysis 
itself not only depicts but also constructs the issues it deals with in a particular 
manner. 
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We identify two major transformations in ELSA research on biobanks and 
consequently three ‘orders of ELSA expertise’, whereby the concept of ‘order’ points 
to a change of emphasis in what counts as a concern in ELSA expertise. However, the 
orders we introduce have not replaced each other. Rather, they overlap, complement 
and superimpose each other. Therefore, our distinction is not meant to highlight clear-
cut historical changes but to try to deliver a conceptual framework to detect shifting 
trends and offer some explanations for each of the changes that are routed in wider 
governance paradigms. 
 
We will argue that the first order of ethical assessment of biobanks was mainly critical 
in tone. To some extent, this was a reaction to market-oriented visions and very 
optimistic – perhaps too optimistic – expectations about the value of novel biobank 
projects.5 As a consequence, ELSA research focused on issues such as the protection 
of donors’ privacy and their rights, which were debated in a situation of regulatory 
uncertainty about the operational requirements of biobanks. 
 
The second order of ELSA expertise responded to the problems raised in the first 
order. Development of national regulation and international harmonisation introduced 
regulatory solutions to many ethical, legal, and social concerns of biobanking – the 
procedure of informed consent being the most well-known example.6 However, 
different types of privacy problems have still been the constant companions of 
biobank projects during the last decade. Moreover, the second-order expertise adopted 
a paradigm in which biobanks have been conceptualised as a ‘public good’ and 
donating tissue and data was framed as an act of solidarity.7 We argue that the 
viewpoint that biobanks represent a public good per se became widely accepted, and 
this consensus about the value of biobank research resulted in the framing of opposing 
arguments as issues of privacy – generally acknowledged public good can be 
contested by referring to private rights. 
 
This project of the second-order ELSA research has been effective. It helped to absorb 
a great deal of uncertainty in a phase when biobanks turned from ‘expensive visions’ 
into ‘expansive practices’ and proved to be capable of being quite stable 
sociotechnical arrangements. At the same time, the growing complexity of 
transnational biobank projects, new uncertainty about the value and outcomes of these 
projects, and ongoing debates about benefit sharing,8 privacy,9 and types of consent10 
have triggered what we call the third order of ELSA expertise – new procedural and 
reflexive configurations in governing biobank infrastructures and their utilisation. The 
last section of this article shifts attention towards this third order that we identify on 
the horizon of ELSA discourses: an order that accentuates reflexive awareness of 
ambiguity and continuing reexamination of regulatory standards. 
Methodological remarks 
For the purpose of this article we have collected and read a broad range of articles that 
addressed ethical and governance issues in relation to the practice of creating and 
running biobanks. These appeared mainly in a) social science or humanities 
periodicals b) ‘life science’ journals in which these kinds of articles mainly appeared 
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as commentaries or opinion pieces, and c) edited volumes on biobank topics. 
Moreover, our analysis included texts that have been intensely referenced by 
academic articles – mainly project reports and statements of regulatory or ethics 
bodies. The material has been gathered through extensive literature searches and has 
been compiled in an Endnote© database consisting of more than 500 articles dealing 
with biobanks and related life science issues.  
 
An initial analysis of the database clearly showed that the issues of ‘privacy’ and 
‘consent’ have accompanied biobanking for more than 15 years now. In the re-
analysis of the material we concentrated on different ‘justificatory logics’11 in the 
field of biobanking where these main issues were addressed. We then made an effort 
to discover patterns of argument that would share core assumptions and would show 
similar conceptual and normative orientations. As we will demonstrate, we found that 
it was possible to group the justificatory logics according to three different discursive 
orders that appeared to be linked to different conceptualisations of the ‘public’, and 
thus the ‘public good’, on the one hand, and to changes in the basic social role or self-
understanding of the ELSA community on the other hand. We do not claim that our 
analysis captures everything that has been published in this domain, but we suggest 
that our analysis, building on our database, reflects the most relevant lines of the 
debates we were interested in.  
Biobanks as sociotechnical arrangements 
The term ‘biobank’ refers to a variety of social and technical arrangements for the 
collection, storage, and exchange of biological materials and associated medical and 
lifestyle information. While collections of biological materials, e.g., pathological 
collections, are as old as modern biomedicine, with the inception of molecular 
medicine in the late 1990s such collections have garnered new interest.12 It was 
widely argued that establishing large collections of tissue samples and enriching these 
materials with clinical and medical data and lifestyle information could significantly 
improve or even ‘revolutionise’ biomedical research and enable a new understanding 
of complex diseases.13 The launch of the first big, population-based biobanks in 
Iceland, Estonia, and the United Kingdom triggered intensive bioethical debates and 
controversies. A decade after these controversial beginnings, biobanks seem to have 
acquired stability. They are no longer as controversial as they used to be, and they 
operate in an increasingly standardised administrative and legal context. They are 
widely recognised as an important infrastructure for biomedical research and can act 
as research-infrastructure hubs14 in the knowledge-based bioeconomy.15 At the same 
time, new challenges are emerging as biobanks move from the national to the 
international scale. Indeed, while in the past a single biobank of sufficient size seemed 
to be the only essential, nowadays the capacity for connectivity in – increasingly 
international – biobank networks seems to be at least equally important. Indeed, 
efforts to create transnational biobank networks have been institutionalised all over 
the world.16  
 
Maintaining a biobank requires assembling numerous people, organisations, and 
technical procedures in a legitimate manner. The normative issue of any biomedical 
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research today, namely ‘how people should be gathered into the research process?’,17 
has become a highly complex one in relation to the establishment and maintenance of 
biobanks and biobank networks. ELSA research on biobanks has addressed the 
questions and solutions through the framings that we call ‘orders’, which have 
suggested different ethically and socially justified procedures for collection, storage, 
and distribution of biobank material. 
The first order – high expectations of genetics confront opposition and concern 
During the 1990s, many bioethicists and social scientists were concerned about the 
implications of the very optimistic scientific expectations of genetic medicine and 
associated pursuits for commercial exploitation of biological material and medical 
information being collected in national biobanks. A critical – even dismissive – 
approach evolved as a core element of the first order of ELSA research on biobanks. 
To some extent, the concerns typical of the first order of ELSA research were shaped 
by the first biobank initiative that gauged broad interest: the biobank project in 
Iceland. 
 
The Icelandic biobank project, based on a partnership between the private company 
deCODE genetics and the Icelandic government, became a central point of reference 
for an international debate about the ethical, juridical, and political problems of 
biobanking. deCODE genetics was envisaged as a major ‘road-building project’ for 
medical genetics, parallel to the Human Genome Project (HGP), which epitomised 
molecular genetics as ‘Big Science’.18 The aim of the Icelandic project was to 
integrate three databases: genealogical records, medical records collected in public 
healthcare, and a database of blood samples for genetic analysis. The project 
provoked opposition both inside Iceland and outside the country, although for 
different reasons. Importantly, most critics were not against biobanking in general; 
what was opposed was the particular way in which this biobank was organised, the 
overtly commercial emphasis, and the proposed public-private partnership model.19, 20  
 
Within Iceland, the main opposition to the biobank project came from Mannvernd, the 
Association of Icelanders for Ethics in Science and Medicine, and its main 
spokespersons were physicians, biologists, geneticists and philosophers.21 Paralleling 
Cook-Deegan’s account of the politics of the HGP,22 the struggle was most intense 
within the scientific and medical community itself and was mainly about the right 
structure for such a research infrastructure project, the right way to do science in 
general, issues of patentability, and the importance and effects of different strategies 
of commercialisation. However, the main proponents no longer exchanged their 
arguments in a purely academic setting, where they would argue in order to convince 
their respective opponents. The debate had become public and the rationale was to 
win over the support of large parts of the population. The opposition propagated the 
fear that the project was running under unfavourable conditions either for the general 
population or for individual citizens. However, it seemed that the supporters of the 
project were able to win over more allies than their counterparts. A Gallup survey in 
April 2000 showed that more than 80 per cent of the Icelandic population was in 
favour of the project.23 
© ESRC Genomics Network. 
18          Genomics, Society and Policy 
             2011, Vol.7 pp.47-64 
 
 




The critics resorted to well established bioethical and juridical principles that had their 
roots in post-Second World War medical ethics and focused on the protection of 
subjects and patients in experimental research and clinical trials. They emphasised 
infringements of informational privacy on the one hand and decisional privacy or 
autonomy on the other hand.24, 25 This focus transcended the domestic realm. 
Subsequently, the international debate on the Icelandic biobank project tended to 
spotlight issues such as exploitation, data protection and informed consent.26 In 
particular informed consent, the contract-like, individual approval of the use of 
samples and data in a variety of research projects became presented as the solution to 
the ethical problems in other national biobank initiatives, also serving as the means to 
legitimate biobanking.27 
 
However, the idea that large-scale biobank projects burdened with scientific and 
commercial expectations could not be fully examined by these ‘old’ tools, was now 
gaining prominence.28, 29 It seemed that the existing standards of medical ethics did 
not fit into the new organisational form of technology any longer, and a lack of 
adequate regulation was diagnosed. From these starting points, the first-order ELSA 
expertise focused on protection of the individual and privacy through better 
regulation. The new regulatory efforts were also a reaction to a market-oriented liberal 
strategy promoted by the proponents of the Icelandic database project. The second-
order of ELSA expertise grew from the identified problems and discrepancies in 
ethical and legal regulation. 
The second order – securing donations through regulation and the promotion of 
biobanks as public goods 
The Icelandic project was followed by other biobank projects in the UK, Estonia, 
Germany, France, Austria, Japan, Israel, and several Scandinavian countries.30 The 
establishment of big national biobank projects like the UK Biobank and the 
development of biobanking activities toward transnational information networks (e.g., 
BBMRI) coincided with the shift from genomics to postgenomics  and a new focus on 
‘genomic diversity’ after the HGP was completed.31  
 
As the new approaches in molecular medicine required both larger amounts of and 
more diverse data, the demand for stable systems and arrangements for the circulation 
and exchange of research data and associated medical information across national 
borders became more intense. 
 
The expansion of national biobanks and the launch of transnational biobank networks 
in the first decade of the 21st century, especially in Europe, took place under the 
influence of the macro-political discourse of the so-called ‘knowledge-based 
economy’ in which governments all over the world stressed the importance of 
scientific knowledge as a factor of production. The goal has been to promote 
economic development and population health through promoting science.32, 33  
Biobanks can be regarded as one practical realisation of this policy agenda at the 
national and transnational levels.34, 35 On the European level their institutionalisation 
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became connected to the programme of the European Research Area (ERA) and the 
subsequent establishment of the European Strategy Forum for Research 
Infrastructures and most important through several funding opportunities for 
European research infrastructures in the 7th Framework Programme of the European 
Union.  
 
On the European and on national levels the activities for building ‘infrastructures’ for 
biomedical research were now more directly governed by public-sector funding 
bureaucracies than in the Icelandic case. At least, direct investment and involvement 
of for-profit businesses in biobanking was the exception rather than the rule. 
 
It seems to be possible to situate the changes in biobank policy discourse in these 
larger developments. As a consequence of these techno-scientific and political-
economic shifts and as a reaction to the problems of perception that ordered the policy 
space in the first phase of biobank expansion, new ways of addressing ethical, legal 
and social issues emerged and stabilised in what we term the ‘second order’ of ELSA 
research on biobanking. This order never replaced the first one altogether. In 
particular, concern over privacy problems continued to be a focus of ELSA 
discussions. However, while the first order of ELSA research was antagonistic and 
highly critical, the emerging second order of ELSA expertise seemed to be more 
lenient toward biobanks. Many ELSA experts seemed to be confident that biobanks 
were per se important tools to promote science, and in line with the key features of the 
discourse of the knowledge-based economy, tended to assume that this would lead to 
improvements in public health and overall well-being of society.36  
 
The tone of the academic commentaries started to change. Biobanks began to be 
framed as ‘public goods’, and there was an ongoing commitment to promote their 
public acceptance.37 While the first order had identified possible problems and risks 
associated with biobanks, the new ELSA academic discourse turned toward a 
pragmatic rationale and focused on finding solutions to problems such as data 
protection, more adequate procedures of informed consent, and governance 
models.38,39,40 The underlying vision was that firm moral and juridical principles 
developed by experts in bioethics and medical law could provide the foundations for 
regulations and guidelines that, in turn, could make the nontechnical dimensions of 
biobank infrastructure manageable. This work was seen as instrumental in fostering 
the social robustness of research41 and in providing research projects with the 
authority they needed in order to operate successfully in the current political and 
economic environment. The aim was to stabilise biobanks by increasing regulatory 
certainty. Biobanks had transformed from an unsettling source of concern to resources 
that could be properly managed. ELSA expertise, it was argued, could help in this 
endeavour. In this context, many ELSA experts adopted the term ‘governance’ to 
refer to legally and ethically sound management of biobanks.42 
 
This new order of ELSA research included the idea that the management of biobanks 
should actively promote public participation in biobank activities and popular 
acceptance of the collection and utilisation of biobank materials. Such a shift is not 
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only detectable in the discourse of ELSA expertise; it is also visible in the manner in 
which new national biobank initiatives were set up after the Iceland case, around the 
turn of the millennium. The case of the UK Biobank, in particular, demonstrates that 
the international community had learned many lessons from the Icelandic endeavour 
and, as a result, a strong ethical and governance framework was created before the 
launch of the biobank.43, 44 Informed consent and privacy of the participants were 
again central issues in debates surrounding the UK Biobank. But even though the 
focus of the discussion was the protection of individual rights and privacy, this 
actually served to secure public trust in the UK Biobank, helping to solve the problem 
of attracting enough participants faced by all population-based biobanks.45 
 
National harmonisation and standardisation of legal and ethical procedures were also 
influential in ELSA discourse on transnational biobank networks. To identify best-
practice models, scholars undertook comparative national case studies and legal 
analysis. In addition, international bodies like the HUGO Ethics Committee,46 
UNESCO,47 the Council of Europe,48 and the OECD49 developed and published 
opinions and guidelines for biobank projects. Projects like P3G, PHGEN, PHOEBE, 
PRIVILEGED, BBMRI, and many others collected and archived the most relevant 
legal norms and guidelines on national and international levels and produced a battery 
of generic tools to be used in biobank administration and management to increase 
efficiency and harmonisation in collection, storage, and circulation of materials and 
information in biomedical research. Almost all these efforts built on the implicit or 
explicit association of biobanks with the public good. This equation assured a certain 
level of organisational certainty because of its promise of more stable financing and a 
willingness to donate genotype material and phenotype data. 
 
While seeking “ethical frameworks that are sufficient to mediate between the 
competing interests at stake”,50 scholars involved in the ‘communitarian turn’ argued 
that the bioethics community was trending towards approaches that emphasised the 
ideal of solidarity, as expressed by participation in research for the public good, 
instead of focusing on ‘mechanisms for obtaining informed consent and protecting 
confidentiality’. The concept of biobanks as global public goods was based on 
attempts to envision a movement of ‘genomic solidarity’, which would be nurtured by 
the promise that improved health lies at the end of the genomics rainbow. In the case 
of human genetic databases, so the argument went, constitutive solidarity would be at 
stake: individuals might perceive that they have an interest in common, namely better 
health care, and they might choose to get together to create a genetic database.51 
 
The “Statement on Human Genomics Databases” by the HUGO Ethics Committee is 
an illuminating example of the second order discourse and its central arguments 
reappear in core academic contributions.52 It states:  
 
Proposing that some of the principles and recommendations that 
follow may apply to both human and non-human genomic databases, 
The HUGO Ethics Committee adopts the following principles as a 
basis for its recommendations: 1) Human genomic databases are 
global public goods. 2) Individuals, families, communities, 
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commercial entities, institutions and governments should foster the 
public good.53 
 
Once the bioethical policy discourse incorporated this ‘public good’ approach toward 
biobanks, they were inclined to treat any act of resistance against them as an instance 
of a (manageable) ‘privacy problem’ on the part of individual donors. Within the 
discursive universe of second-order ELSA research, this followed almost logically: 
once biobank projects have become identified with the ‘public good’, everything that 
runs counter to them must hence be ‘bad’ from a public-interest perspective and can 
only legitimately be ‘good’ from a purely ‘private’ perspective – which, even if it has 
to be respected and valued to a certain degree in liberal societies, is not readily a 
legitimate basis for public policy. Fundamental disagreements about ideas and 
advantages of the public good, associated with biobanks, became therefore 
inconceivable. Attention could be directed to protecting donors or lay people from 
abuse and misuse of their data. However, ethical reflection increasingly concentrated 
on citizens’ sense of duty to promote research in the name of the public good.54, 55 
 
In a way, the idea of an altruistic ‘biological citizen’ was utilised in order to point out 
that people actually want to participate as donors in order to make genomic-based 
health research and drug development possible and more efficient. According to this 
line of thought, the motivation of individual citizens goes beyond their wanting to 
participate in biobank initiatives because it could benefit their own health; indeed, 
participation is viewed as an act of almost obligatory solidarity and responsibility. In a 
way, bioethics changed from an ethics for the life science research community to an 
ethics of citizens who have rights and responsibilities in relation to the biomedical 
research complex.56,57 Arranging sufficient protection of informational privacy, data 
protection, and an acceptable consent procedure in biobanks was seen as helping to 
achieve a satisfying donor participation rate. Such an arrangement would still respect 
personal autonomy, a leading principle of bioethics, by establishing a relationship 
resembling a contract between a donor and a biobank. The shift to this communitarian 
framework solidified the turn to a new order of ELSA expertise, which was 
committed to the promotion of biobanks and which envisaged its own role as the 
generation of the type of expertise that could help to manage problems such as data 
protection. 
 
At the same time, it was recognised that informed consent often loses its ethical 
significance and becomes an empty procedure, because of the unspecified and 
uncertain uses of samples and information deposited in the biobanks. Consequently, 
the practice and even the notion of informed consent were called into question.58 
Many scholars of the second order connected their emphasis on biobanks as a public 
good with suggestions for open or broad consent.59 The argument was that biobanks 
were able to serve as a public good only if they were able to use the material for 
future research towards new, currently unanticipated purposes. 
 
One example of how the concerns identified by first-order discourse have been turned 
into regulative measures in the second order is the five-pillar concept proposed by the 
German Ethics Council.60 It focused on protecting the interests of donors while 
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preparing the ground for massive biobank research expansion. Again, the main 
assumption was that a certain type of regulation must be created in order to maintain 
high participation rates for biobank projects that aim at promoting the public good.61  
 
The five-pillar concept included a proposal for biobank secrecy, which would 
safeguard against third-party access to biobanks, whether by state agencies or by 
nongovernment parties such as insurance companies and employers. In addition, the 
ethics review committee of the biobank should preapprove all research projects that 
might use donors’ personal data. But by way of reciprocation the proposal turned 
away from informed consent, because it seemingly conflicted with the freedom of 
science. The Council therefore argued for legislation that explicitly provides the 
possibility for giving broad consent.62 Once again, the assumption was that a 
combination of measures that protect personal data from third party intrusion on the 
one hand, together with expert decision-making bodies that take into account ethical 
and technical arguments on the other, would increase levels of public biobank 
acceptance. 
 
However, in all these regulatory and ethical proposals privacy was treated as a 
protective means value. This means that it is assumed that “we value privacy because 
we could be harmed by the use or misuse of personal information about us”.63 But 
‘privacy’ is an essentially contested and ambiguous term.64 It is potentially loaded 
with heterogeneous motifs and interests that go beyond the wish to be adequately 
protected from the misuse of personal information.65, 66 In fact, most privacy conflicts 
are primarily struggles about the boundaries between the public and the private, and 
the significance of those boundaries.67 People are not only worried about their 
personal privacy because they want to be protected. Often, they use claims to privacy 
in order to demand certain levels of influence. Active citizens are sometimes 
apprehensive about the goals and purposes of biobanks and demand that their voices 
are heard about the issue how the public good should be actively promoted.68 
The third order – recognising complexity and uncertainty through reflexivity 
With the previous orders of ELSA research, many problems and concerns were 
identified, regulatory measures to control these issues were taken, and a fairly stable 
working environment for biobanks was created. These were important achievements, 
and we do not claim that the certainty it created will decrease in importance. Rather, 
our analysis of third-order ELSA research seeks to add elements that complement a 
drive for regulatory certainty. It points towards more inclusive mechanisms that 
promise to increase the quality and speed of organisational learning in biobank 
arrangements, which might be crucial in order to operate successfully under the 
conditions of knowledge-based societies.. Increasingly, however, economic 
fluctuations, political transformations, local controversies and changes in the attitudes 
about value of genomic knowledge are creating uncertainty. According to several 
authors, the pronunciation of sound regulatory solutions in the second order is not 
necessarily enough in this new context.69, 70 Biobanking as a practice is in constant 
development. So are its economic and cultural contexts. Until recently, for example, it 
was more or less assumed that the future of genomics was a bright one. 
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Groundbreaking scientific findings as well as commercial returns were and still are 
promised and expected. However, considerable doubts about such promises are 
appearing on the horizon.71 As a reaction, new approaches that deal with diverse 
viewpoints have been proposed. 
 
Many scholars have already pointed to changes of emphasis and called for new 
approaches to evaluate and govern biobanks. Ursin, Hoeyer, and Skolbekken,72 for 
example, have analysed how informed consent in its various forms has been used 
strategically in the governance of biobanks. They were able to show how 
concentration on informed consent has geared discussion away from other concerns 
and from calls for ELSA research that goes beyond informed consent. In a similar 
way, Corrigan and Petersen73 have demonstrated how problems associated with 
biobanks have been framed as risk issues for participants. In a further step, the 
regulation of these risks has been treated as the complement of the problem of 
securing large-enough participation rates. Regulation and ‘ethical’ governance 
structures have been designed so as to generate public trust. However, Corrigan and 
Petersen argue that public engagement and consultations designed to tackle this 
problem have not addressed the concerns of the public but have instead only served to 
legitimate biobank projects without questioning the promises on which their 
promotion actually rests. 
 
There is an increasing amount of research that emphasises the idea that concerns 
about bioinformational privacy of potential donors in such projects should no longer 
be treated simply as calls for more and better protection of privacy from harm or 
misuse of these particular pieces of information. These questions about data 
protection and informed or broad consents emerged in correspondence with the 
second-order ELSA expertise. However, they are not necessarily congruent with the 
concerns about or demands for different types of care and new forms of distributional 
fairness74,75 that could be expressed in political spaces opened up by reflexive 
reasoning. Viewpoints on biobank issues are diverse and can encompass wider 
economic and societal issues – like the processes of scientific and economic 
utilisation of the information and samples they provided.76, 77, 78 They are part of a 
struggle for power and control in a policy area that is highly dependent on the ongoing 
investment of public money.79  
 
The new order of ELSA research that is emerging surpasses the public good/privacy 
dichotomy by acknowledging the ambiguity of peoples’ motives and different 
contexts of participation. It examines ethical regulation beyond informed consent and 
data protection, and recognises the values (and limits) of different modes of public 
engagement. We propose that one function of this type of ELSA research is 
systematically to increase inner-organisational uncertainty and reflexivity in biobank 
projects by introducing different outsider perspectives into routine working 
procedures. This might appear paradoxical; yet, we argue that the purpose of this is to 
create new capacities for learning how to adapt to a not -controllable future through 
observing changes in the organised infrastructure’s environment. This approach 
resembles some crucial elements of Dirk Baecker’s sociological analysis of recent 
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shifts in management styles of other domains. The search for solutions for seemingly 
given or naturalised problems is replaced with the search for new questions and 
perspectives that enable the detection of chances and threats through distortions of 
routine organisational processes.80 In this respect it is crucial to take into account that 
typical rule-based, bureaucratic organisations are social systems that routinely 
discourage learning. They are inflexible and therefore limit their interaction with their 
uncertain environment, by defining relatively narrow agendas and limited 
communications channels.81, 82 Rule following is more important than innovation, 
which opposes the premises of the contemporary programme of knowledge-based 
economies. Substantive rationality became increasingly replaced with reflexive 
rationality and more ‘intelligent’ organisations are able to adhere to the routines that 
are essential for their survival but hopefully ‘naïve’ enough to test whether the 
assumptions their routines rest on are still valid.83 
 
Similarly, the focus of many ELSA researchers has therefore shifted from generating 
regulatory answers (although this will remain important) to helping to create ways to 
test whether the assumptions that are built into a research system or infrastructure 
about its (social) environment are still valid. The ELSA scholars are questioning the 
functioning logics of biobanks – for example the idea that population biobanks should 
not return individual research results.84 They are also becoming involved in co-
developing and arguing for interactive settings of digital governance in which routine 
biobank settings and processes are approached from different angles and learning can 
occur.85, 86 
 
International networks of biobanks are regarded as needing new ways of thinking 
about governing biobanks. The given goal of generating a public good becomes even 
more difficult to define and has to be evaluated constantly, so ‘public good’ becomes 
explicitly (re-)defined in this process.87 The third order ELSA research emphasises 
communicative processes that bring different perspectives, opinions, and interests to 
the table in order to serve as common problems that unite actors and stakeholders. 
This procedural rationality is very much the essence of governance processes.88 In this 
sense, problems (like privacy contestations) are becoming resources for governance 
processes that must solve how to bring together a heterogeneous set of actors around a 
common policy task. An ethics of conviction, which assumes a given hierarchy of 
values, becomes increasingly complemented with an ethics of responsibility that 
assumes that a value conflict is the context of every moral endeavour and no hierarchy 
of values can be stipulated. Governance is therefore no longer understood only as a 
means to solve conflicts, but rather as a set of attempts to manage them in innovative 
ways and critically understand and assess identified problems and concerns.89 
 
Instead of assuming that biobanks are public goods per se, more and deeper analysis 
about the circumstances in which biobanks are treated as public goods is needed. The 
public good/private concerns conceptual framework offered by communitarian ethics 
is not suited to answering these questions in an empirical fashion.90 Working on this 
task means acknowledging, facing, accepting, coping with, and even embracing 
uncertainty in order to increase communication and connectivity. Therefore, third-
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order ELSA research can turn the explicitly strategic assumption of the 
communitarian turn in ethics into strategic questions that can be systematically 
reactualised from time to time: Is this specific type and practice of biobanking 
considered to be for a public good? By whom? What motives are presented? In what 
ways do perspectives of internal observers differ from perspectives that are held 
outside of the core biobank organisations? In short, the emphasis is shifted to the 
different ways in which stakeholders negotiate and define the public or common good. 
 
The social science literature as well as political practice has developed a substantive 
toolbox for participatory arrangements with different publics, including traditional 
opinion polls, focus groups, citizen juries, and scenario workshops.91 Although many 
of these engagement processes have served as legitimating tools that have not really 
been incorporated into the actual decision-making process, each of these governance 
instruments potentially creates a different but limited perspective of what it means to 
be a citizen or a political subject. Likewise, the third-order ELSA expertise can offer 
solutions to integrate engagements in manners useful to biobank insiders as well as to 
outside stakeholders. Useful models of how this must be done in the field of 
biobanking can be found, for example, in the activism of patient groups and 
networks,92,93 but the greater challenge might be including more diverse groups and 
their views about political and socioeconomic topics such as the usefulness of 
biobanks, the effects of internationalisation, and the commercialisation of research.94  
 
In addition, reconsidering biobank governance from a procedural aspect, which aims 
at multiway communication between a potentially infinite constituency, throughout 
the life cycle of biobanks would also address the problem of blind responsibility that 
is created by the altruistic genomic solidarity reasoning, where donors are expected to 
take responsibility for the public good by participating in biobank efforts without 
knowing their consequences.95 When future uses and institutional configurations of 
biobanks are not known to donors (as is acknowledged), they are bearing 
responsibilities for issues beyond their control. Implementing transparency and 
procedural communicative arrangements lessens this blind responsibility and creates 
actual co-responsibility for delivering common goods.96, 97 Clearly, it is not the duty 
of the involved publics to manage and govern everything that happens in biobanks. 
Therefore, it is crucial to reflect donors’ expressed motives, interests, and concerns 
onto the biobanking practitioners and their everyday work, where for example 
categories and conceptions about race and diseases are still being produced in 
manifold ways.98 ELSA expertise can mediate such complicated social relations 
between biobanking organisations and a society that is becoming ever more 
heterogeneous and complex. The task is delicate since it has to be delivered without 
being prone to the categorical oversimplifications that seem to offer easy ways out of 
political, moral, and ethical conflicts. 
Conclusions 
Biobanks assemble large numbers of people, organisations, and technical procedures. 
This implies multiple expectations, concerns, and opinions about how to collect, store, 
circulate, and deploy tissue samples and molecular and health information in a 
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justifiable manner. ELSA experts have debated, for example, how to attract tissue 
donors, how to secure public trust, and what proper legal and ethical regulations are. 
 
We have identified three orders of ELSA expertise on biobanks that have addressed 
the problems related to biobanking and suggested ethically and socially acceptable 
procedures for collection and distribution of biobank material. The first-order ELSA 
expertise was mainly critical in tone and approached problems of biobanking through 
protection of the donors’ privacy and rights in circumstances where there was 
regulatory uncertainty about the operation requirements of biobanks. The second-
order ELSA expertise introduced regulatory solutions to many ethical, legal, and 
social concerns by the development of national regulation and international 
harmonisation. The idea of biobanks as producers of a public good became a central 
notion in securing sufficient participation rates to biobanks. 
 
We have suggested that a third order of ELSA biobank research that builds on these 
previous achievements is emerging. This order seeks to promote learning processes 
and critical reflexivity. It aims at challenging some of the basic assumptions that have 
guided the academic policy proposals and problem identification processes of earlier 
orders - like the public good/privacy framework - and identifies places for new 
communications and procedural strategies. In that way it offers the biobank 
community new concepts, methods, and insights from perspectives that help to adapt 
to an uncertain and essentially underdetermined future by reintroducing uncertainty 
into already regulated and stabilised organisations. 
 
During the past years, the focus of setting up and running biobanks has changed from 
national sample and information collections to complex transnational organisation of 
biobank infrastructures and international circulation of biomaterial and information. 
Transnational networks that aim to circulate bioinformation with growing efficiency 
operate in an increasingly complex environment filled with uncertainties. On one 
hand, samples and information are collected in local settings where large numbers of 
stakeholders have differing views on risks and expectations about the results and 
goals of biobanks. On the other hand, research and development are conducted in 
global contexts with another set of stakeholders. The task of third-order ELSA 
expertise under these circumstances is to help in identifying the needs of different 
stakeholders and to introduce reflexivity throughout these processes by questioning 
and evaluating existing practices. 
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